Post-marketing Surveillance Study for the Safety of Hexaxim®, a DTaP-IPV- HB-PRP~T Vaccine Administered to Infants From 2 Months of Age in Republic of Korea
Latest Information Update: 06 Feb 2025
Price :
$35 *
At a glance
- Drugs Hib-DTaP-hepatitis B-poliovirus vaccine (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Sanofi Pasteur
- 03 Feb 2025 Planned End Date changed from 9 Apr 2026 to 13 Apr 2026.
- 03 Feb 2025 Planned primary completion date changed from 9 Apr 2026 to 13 Apr 2026.
- 03 Feb 2025 Status changed from not yet recruiting to recruiting.